Sana Biotechnology (SANA)
NASDAQ:SANA
Top Page
Sana Biotechnology
(NASDAQ:SANA)
Select Model
Select Model
Rating:46Neutral
Price Target:
$3.00
▼(-1.64% Downside)
Action:ReiteratedDate:03/04/26
Score is held down primarily by weak financial fundamentals (no revenue, sustained losses, and ongoing cash burn with a weakening balance sheet) and a soft technical setup (below key moving averages with negative MACD). Positive corporate developments and financing flexibility provide some support but do not fully offset execution and funding risk.
Positive Factors
Clinical progress (UP421/SC451/SG293)
Twelve‑month human data showing durable, immunosuppression‑free islet function materially strengthens the scientific foundation for Sana’s hypoimmune platform. Coupled with planned IND/Phase 1 progress for SC451 and SG293, these results raise the long‑term probability of clinical validation and downstream partnerships or commercialization.
Negative Factors
No revenue / persistent losses
Sana remains pre‑commercial with zero reported revenue and multiyear operating losses. Absent product sales, the company depends on external financing to fund R&D and operations, leaving long‑term value creation tied entirely to clinical success and partner/licensing outcomes rather than organic cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical progress (UP421/SC451/SG293)
Twelve‑month human data showing durable, immunosuppression‑free islet function materially strengthens the scientific foundation for Sana’s hypoimmune platform. Coupled with planned IND/Phase 1 progress for SC451 and SG293, these results raise the long‑term probability of clinical validation and downstream partnerships or commercialization.
Read all positive factors
Sana Biotechnology (SANA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$813.94M
Dividend YieldN/A
Average Volume (3M)2.43M
Price to Earnings (P/E)―
Beta (1Y)1.37
Revenue GrowthN/A
EPS Growth31.16%
CountryUS
Employees194
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.21
Shares Outstanding266,866,880
10 Day Avg. Volume3,390,584
30 Day Avg. Volume2,429,628
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)6.41
Price to Sales (P/S)0.00
P/FCF Ratio-7.12
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-282.01
Enterprise Value/Ebitda-4.70
Forecast
1Y Price Target
$9.50Price Target Upside211.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.64
Revenue Forecast (FY)N/A
Sana Biotechnology Business Overview & Revenue Model
Company Description
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology...
How the Company Makes Money
null...
Sana Biotechnology Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
20
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -12.75M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -178.21M | -255.33M | -268.58M | -256.94M | -345.84M |
| Net Income | -244.17M | -266.76M | -283.25M | -269.48M | -355.93M |
Balance Sheet | |||||
| Total Assets | 416.89M | 501.02M | 565.30M | 822.72M | 1.13B |
| Cash, Cash Equivalents and Short-Term Investments | 138.38M | 152.50M | 205.19M | 423.96M | 551.00M |
| Total Debt | 78.86M | 94.20M | 104.10M | 108.25M | 110.94M |
| Total Liabilities | 256.01M | 250.52M | 277.79M | 323.40M | 400.90M |
| Stockholders Equity | 160.88M | 250.50M | 287.51M | 499.31M | 728.50M |
Cash Flow | |||||
| Free Cash Flow | -144.77M | -256.58M | -273.61M | -310.93M | -280.92M |
| Operating Cash Flow | -143.83M | -223.15M | -253.58M | -290.05M | -251.05M |
| Investing Cash Flow | -40.24M | 17.45M | 172.01M | 210.56M | -245.80M |
| Financing Cash Flow | 128.73M | 199.75M | 31.65M | 4.91M | 631.75M |
Sana Biotechnology Technical Analysis
Negative
3.05
Price Trends
3.78
Negative
4.05
Negative
3.94
Negative
Market Momentum
-0.26
Negative
43.02
Neutral
31.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SANA, the sentiment is Negative. The current price of 3.05 is below the 20-day moving average (MA) of 3.11, below the 50-day MA of 3.78, and below the 200-day MA of 3.94, indicating a bearish trend. The MACD of -0.26 indicates Negative momentum. The RSI at 43.02 is Neutral, neither overbought nor oversold. The STOCH value of 31.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SANA.
Sana Biotechnology Risk Analysis
Sana Biotechnology disclosed 82 risk factors in its most recent earnings report. Sana Biotechnology reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sana Biotechnology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $1.06B | -10.26 | -34.23% | ― | 522.13% | 62.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $612.07M | -2.57 | -178.61% | ― | 647.13% | 26.79% | |
49 Neutral | $1.24B | -16.13 | -56.64% | ― | -36.36% | -945.72% | |
47 Neutral | $4.69B | ― | -31.53% | ― | -81.10% | -99.21% | |
46 Neutral | $813.94M | -4.22 | -141.99% | ― | ― | 31.16% | |
44 Neutral | $255.45M | -1.14 | -523.29% | ― | -24.90% | 7.19% |
* Healthcare Sector Average
SANA
Sana Biotechnology
3.20
1.72
116.22%
GERN
Geron
1.66
0.28
20.29%
EDIT
Editas Medicine
2.67
1.64
159.22%
CRSP
Crispr Therapeutics AG
49.51
16.86
51.64%
TSHA
Taysha Gene Therapies
4.37
3.15
258.20%
PRME
Prime Medicine, Inc.
3.32
1.91
135.46%
Sana Biotechnology Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
Sana Biotechnology Updates ATM Program to Support Development
Positive
Mar 3, 2026
Sana Biotechnology, Inc., based in Seattle and listed on Nasdaq as SANA, operates in the biotechnology industry, focusing on creating and delivering engineered cell and gene therapies. The company’s key platforms include its hypoimmune techn...
Executive/Board Changes
Sana Biotechnology Names Brian Piper as New CFO
Positive
Feb 17, 2026
On February 17, 2026, Sana Biotechnology appointed Brian Piper as Executive Vice President, Chief Financial Officer, Treasurer, and Principal Financial Officer, ending CEO Steve Harr’s interim role as acting principal financial officer. Pipe...
Business Operations and StrategyProduct-Related Announcements
Sana Biotechnology Highlights Diabetes Cell Therapy Advances at Conference
Positive
Jan 14, 2026
At the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, Sana Biotechnology presented updated data showing that UP421, its hypoimmune-engineered primary pancreatic islet cell therapy, survived and functioned for at least 12 months...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.